Avenzo Therapeutics is a clinical-stage biotechnology company based in San Diego, California, dedicated to developing next-generation oncology therapies. The company's pipeline includes potential best-in-class small molecules and antibody-drug conjugates (ADCs), targeting key enzymes involved in cell cycle regulation and specific cancer markers. Avenzo's lead drug candidates, including AVZO-021 and AVZO-023, are being studied for the treatment of advanced solid tumors and HR+/HER2- metastatic breast cancer, while its ADCs focus on bispecific targeting of cancer cells.